国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Chinadaily.com.cn
 
Go Adv Search

Novo Nordisk has innovative prescription for expansion

Updated: 2011-11-02 14:27

By Liu Jie (China Daily)

  Comments() Print Mail Large Medium  Small

Novo Nordisk has innovative prescription for expansion

Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk A/S. [Photo/ China Daily]

BEIJING - The world's largest insulin producer, Novo Nordisk A/S, said it would not pursue mergers and acquisitions (M&A) in China but would instead expand by strengthening its research and development (R&D) activity, building manufacturing facilities and enhancing education.

"A few multinational companies made acquisitions (in China) to get entry into the generic medication and (over-the-counter) business.

"Novo Nordisk is another kind of company. We want to concentrate on innovative new drugs," Ronald Frank Christie, senior vice-president of Novo Nordisk and president of Novo Nordisk (China) Pharmaceuticals Co Ltd, said on Monday.

According to Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk A/S, the Denmark-based company has made "substantial" investments in China in R&D, manufacturing and education.

He said the company will "continue to invest in the emerging market, also the fastest-growing market for Novo Nordisk".

The drugmaker, which has focused on diabetes for more than 80 years, said last year it would invest more than $100 million to expand its R&D center in Beijing and double its R&D staff to 200 within five years.

The center in Beijing is Novo Nordisk's largest such facility outside its headquarters in Copenhagen.

"We are not interested in bringing in generic (products). We are only interested in bringing new drugs to the market, to make a difference," said Christie.

Novo Nordisk, which produces two-thirds of the insulin used in China, also announced in 2008 it would invest $400 million to build a manufacturing base in Tianjin, which is expected to go into full operation in 2012. That base would be the largest manufacturing facility for the company outside its home market of Denmark.

In addition to meeting local demand, the Tianjin base will also export products.

"We believe that the capacity of manufacturing (in Tianjin) will supply our demand at least for the next three or four years," said Sorensen. "Perhaps, two years from now, we may have to consider further investment, but it's too early to talk about that."

Novo Nordisk has sought to provide consumer education and offer training to local doctors. In addition to constant community-training courses, it linked up with the Ministry of Health and Chinese academic institutes to hold international diabetes forums and train grassroots medical care practitioners.

Statistics from the Ministry of Health show that nearly 100 million Chinese have diabetes. The Chinese diabetes drug market will increase to more than $2.8 billion by 2015 from $642 million in 2009, the International Market Analysis Research and Consulting Group said in a report.

According to medical care research company IMS Health, Novo Nordisk, US-based Eli Lilly and Co and French drugmaker Sanofi AS hold about 90 percent of China's insulin market.

Some international pharmaceutical companies, such as Swiss drugmaker Novartis AG and Novo Nordisk's archrival Sanofi, were engaged in M&As with local companies in recent years.

"Different companies have different choices, given their different competitive edges.

"Innovation-focused drug producers in China may face the challenge of high prices compared with generic products and difficulties in getting their products on the nation's essential drug list or into the medical insurance system," said Guo Fanli, an analyst from the domestic research company China Investment Consulting.

 

宜兴市| 东源县| 宕昌县| 阜康市| 临潭县| 安乡县| 闸北区| 呼图壁县| 弥勒县| 广安市| 怀宁县| 论坛| 南岸区| 永康市| 贡觉县| 滨海县| 丁青县| 磐安县| 札达县| 姜堰市| 工布江达县| 冷水江市| 双辽市| 安龙县| 林甸县| 营山县| 开原市| 金堂县| 台北市| 洪泽县| 宜城市| 子长县| 正镶白旗| 南宫市| 宣汉县| 育儿| 德化县| 龙门县| 腾冲县| 英吉沙县| 扎鲁特旗|